Non-invasive glucose Liom offers a world first in non-invasive glucose monitoring, presenting a compelling entry point for outreach to healthcare providers, wellness programs, and insurers seeking preventive health tech with measurable outcomes.

Series A traction Recent substantial funding rounds totaling around 25 million USD and a prior 16.3 million USD round signal strong investor confidence and market validation, creating opportunities to approach strategic partners and potential co-investors or customers seeking proven innovation.

Wellness market fit Operating in wellness and fitness services with a focus on prevention and early detection, Liom is positioned to partner with fitness centers, corporate wellness programs, and health insurers aiming to expand preventive care offerings.

Growth potential With a small-to-mid sized team and revenue in the low to mid seven figures, Liom is likely seeking commercialization partnerships, manufacturing scale, and distribution channels to accelerate market adoption.

Tech and IP signals The emphasis on real-time multi-signal data fusion for glucose insights, combined with a software-friendly tech stack and global reach via an online presence, suggests opportunities for integration with digital health platforms, EHRs, or wearable ecosystems.